Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction
Non-small-cell lung cancer is one of the most lethal cancers in the worldwide. Although Paclitaxel-based combinational therapies have long been used as a standard treatment in aggressive non-small-cell lung cancers, Paclitaxel resistance emerges as a major clinical problem. It has been demonstrated...
Main Authors: | Yimin Lu, Jun Wang, Lei Liu, Lequn Yu, Nian Zhao, Xingju Zhou, Xudong Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
IOS Press
2017-04-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428317698353 |
Similar Items
-
Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, nab-Paclitaxel)
by: Vera eHirsh, et al.
Published: (2014-07-01) -
Ginsenoside Rg5 Sensitizes Paclitaxel—Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel—And Enhances the Anticancer Effect of Paclitaxel
by: Janani Ramesh, et al.
Published: (2022-06-01) -
Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells
by: Amirhosein Maharati, et al.
Published: (2023-07-01) -
Synthesis of Carrier-Free Paclitaxel–Curcumin Nanoparticles: The Role of Curcuminoids
by: Sena Karaosmanoglu, et al.
Published: (2022-12-01) -
Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
by: Frontiers in Oncology Editorial Office
Published: (2014-10-01)